We are live on ! Find out more
PBPIA

Pivotal bioVenture Partners Investment Advisor Portfolio holdings

AUM $280M
1-Year Est. Return 181.4%
This Fund
S&P 500
This Quarter Est. Return
+23.35%
1 Year Est. Return
+181.4%
3 Year Est. Return
+730.97%
5 Year Est. Return
+1,157.4%
10 Year Est. Return
–
AUM
$243M
AUM Growth
+$12.9M
Cap. Flow
+$24.5M
Cap. Flow %
10.07%
Top 10 Hldgs %
99.73%
Holding
11
New
1
Increased
2
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
OCS icon
Oculis Holding
OCS
+$19.9M
2
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$3.08M
3
INZY
Inozyme Pharma
INZY
+$1.46M

Top Sells

Rank Stock Value
1
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$8

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$142M 58.49%
782,008
+16,113
+2% +$3.08M
PCVX icon
2
Vaxcyte
PCVX
$8.93B
$26M 10.7%
693,039
– –
INZY
3
DELISTED
Inozyme Pharma
INZY
$18.4M 7.58%
3,213,586
+552,432
+21% +$1.46M
OCS icon
4
Oculis Holding
OCS
$723M
$17.7M 7.29%
+2,381,196
New +$19.9M
RLYB icon
5
Rallybio
RLYB
$87.1M
$13.7M 5.65%
300,581
– –
ARQT icon
6
Arcutis Biotherapeutics
ARQT
$3.27B
$6.26M 2.58%
569,041
– –
FUSN
7
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$5.88M 2.42%
1,560,982
-2
-0% -$8
VIGL
8
DELISTED
Vigil Neuroscience
VIGL
$5.49M 2.26%
560,595
– –
EXAI
9
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$4.09M 1.69%
772,285
– –
BOLT icon
10
Bolt Biotherapeutics
BOLT
$6.46M
$2.63M 1.08%
94,573
– –
ALGS icon
11
Aligos Therapeutics
ALGS
$45M
$650K 0.27%
29,729
– –

Similar funds

HCM
Hall Capital Management Barrington, Rhode Island $280M AUM 14.82% 1-Year Est. Return
OFCM
One Fin Capital Management San Francisco, California $280M AUM 49.87% 1-Year Est. Return
NCM
NCM Capital Management Ramsey, New Jersey $279M AUM 26.47% 1-Year Est. Return
CCC
Compass Capital Corp Braintree, Massachusetts $279M AUM 28.36% 1-Year Est. Return
PHC
Panoramic Hills Capital Road Town $280M AUM
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
SL
SOF Ltd George Town, Cayman Islands $279M AUM 6.12% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's Q1 2023 Portfolio in Review

As of Q1 2023, Pivotal bioVenture Partners Investment Advisor held 11 positions worth $243M, up 5.6% from $230M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Pivotal bioVenture Partners Investment Advisor deployed $24.5M of net new capital in Q1 2023, opening 1 new position and adding to 2 existing holdings. Its largest new stake was Oculis Holding: 2,381,196 shares worth $17.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Fusion Pharmaceuticals Inc. Common Shares, an estimated $8 trimmed.

  • Pivotal bioVenture Partners Investment Advisor's largest Q1 2023 buy was Oculis Holding: 2,381,196 shares worth $17.7M.
  • Pivotal bioVenture Partners Investment Advisor added most to Karuna Therapeutics, Inc. Common Stock in Q1 2023, an estimated $3.08M increase.
  • Pivotal bioVenture Partners Investment Advisor's biggest Q1 2023 reduction was Fusion Pharmaceuticals Inc. Common Shares, cutting an estimated $8.
  • Pivotal bioVenture Partners Investment Advisor's ten largest holdings make up 100% of its $243M portfolio in Q1 2023.
  • Pivotal bioVenture Partners Investment Advisor opened 1 new position and closed 0 in Q1 2023.
  • Pivotal bioVenture Partners Investment Advisor's portfolio value rose 5.6% quarter-over-quarter to $243M.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q1 2023, filed 12 May 2023.